All In MedTech

FDA Clearance Tracker · P150038-S013

Exablate Model 4000 Type 1.0 and 1.1 System (“Exablate Neuro”)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 22, 2021

Approved

Time to decision

272 days

Received Oct 23, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150038-S013
Device name
Exablate Model 4000 Type 1.0 and 1.1 System (“Exablate Neuro”)
Applicant
Insightec
Applicant location
Tirat Carmel
Received
Oct 23, 2020
Decided
Jul 22, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150038

Device type

Device class
Class III

Every decision under product code POH

FDA's approval statement

As written in FDA's record.

Approval for design changes to the Exablate Model 4000 Type 1.0 & 1.1 System (Exablate Neuro) to address the end-of-life of some of the system components; to support Exablate Neuro Type 1.1 imaging quality improvements to align with the imaging quality improvements approved for the Exablate Neuro Type 1.0 and to address minor software version 7.33 defects and usability aspects.

Source documents

Other decisions for Insightec

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.